ArticleJournal of clinical hypertension (Greenwich, Conn.)2016
Long-Term Effects of Renal Sympathetic Denervation on Hypertensive Patients With Mild to Moderate Chronic Kidney Disease.
Article in Journal of clinical hypertension (Greenwich, Conn.), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Effects of renal denervation on kidney function in patients with chronic kidney disease: a systematic review and meta-analysis.Journal of human hypertension · 2024Pooled it
- Kidney function and markers of renal damage after renal denervation. Does method of measurement matter? The Reshape CV-Risk Study.Journal of clinical hypertension (Greenwich, Conn.) · 2021Trial
- Pulmonary vein isolation combined with spironolactone or renal sympathetic denervation in patients with chronic kidney disease, uncontrolled hypertension, paroxysmal atrial fibrillation, and a pacemaker.Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing · 2018Trial
- 5/6 Nephrectomy as an Experimental Model for Chronic Kidney Disease: New Vasoactive and Antioxidant Therapeutic Targets.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Renal denervation revisited: is patient selection the missing link between failure and success?Clinical hypertension · 2026Review
- Safety and Efficacy of Renal Denervation for the Treatment of Resistant Hypertension in Patients with Chronic Kidney Disease: A Narrative Review of the Literature.Biomedicines · 2025Review
- The Effect of Renal Denervation on Capillary Density in Patients With Uncontrolled Hypertension.Microcirculation (New York, N.Y. : 1994) · 2025Article
- Effect of renal denervation on glucose metabolism in hypertensive patients with and without chronic kidney disease.Clinical kidney journal · 2025Article
- Renal denervation in dialysis patients: long-term outcomes in a real-world setting.Clinical kidney journal · 2025Article
- Renal denervation is effective in reducing blood pressure in patients with CKD.Clinical kidney journal · 2025Review
- Renal nerves in physiology, pathophysiology and interoception.Nature reviews. Nephrology · 2025Review
- Microalbuminuria as a Prognostic Marker in Essential Hypertension.Current medicinal chemistry · 2025Review
- Blood pressure reduction after renal denervation in patients with or without chronic kidney disease.Clinical kidney journal · 2024Article
- Novel Approaches in Chronic Renal Failure without Renal Replacement Therapy: A Review.Biomedicines · 2023Review
- Renal denervation in patients with chronic kidney disease: current evidence and future perspectives.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2023Review
- 2022 Renal denervation therapy for the treatment of hypertension: a statement from the Thai Hypertension Society.Hypertension research : official journal of the Japanese Society of Hypertension · 2023Article
- Insight on Efficacy of Renal Artery Denervation for Refractory Hypertension with Chronic Kidney Diseases: A Long-Term Follow-Up of 24-Hour Ambulatory Blood Pressure.Journal of interventional cardiology · 2022Article
- Renal denervation for mild-moderate treatment-resistant hypertension : A timely intervention?Herz · 2019Article
- 2019 Consensus Statement of the Taiwan Hypertension Society and the Taiwan Society of Cardiology on Renal Denervation for the Management of Arterial Hypertension.Acta Cardiologica Sinica · 2019Review
- Relevance of Targeting the Distal Renal Artery and Branches with Radiofrequency Renal Denervation Approaches-A Secondary Analysis from a Hypertensive CKD Patient Cohort.Journal of clinical medicine · 2019Article
Corrections and comments
- Commented on by
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Thirty patients who underwent percutaneous renal denervation, which was performed by a single operator following the standard technique, were enrolled in this study. Patients with chronic kidney disease (CKD) stage 2 (n=19), 3 (n=6), and 4 (n=5) were included. Data were obtained at baseline and at monthly intervals for the first 6 months. At 7 months, follow-up data were collected bimonthly until month 12, after which data were collected on a quarterly basis. Baseline blood pressure values (mean±standard deviation) were 185±18/107±13 mm Hg in the office and 152±17/93±11 mm Hg through 24-hour ambulatory blood pressure monitoring (ABPM). Three patients with stage 4 CKD required chronic renal replacement therapy (one at the 13-month follow-up and two at the 14-month follow-up) after episodes of acute renal injury; their follow-up was subsequently discontinued. The office blood pressure values at the 24-month follow-up were 131±15/87±9 mm Hg (P<.0001, for both comparisons); the corresponding ABPM values were 132±14/84±12 mm Hg (P<.0001, for both comparisons). The mean estimated glomerular filtration rate increased from 61.9±23.9 mL/min/1.73 m(2) to 88.0±39.8 mL/min/1.73 m(2) (P<.0001). The urine albumin:creatinine ratio decreased from 99.8 mg/g (interquartile range, 38.0-192.1) to 11.0 mg/g (interquartile range, 4.1-28.1; P<.0001 mg/g). At the end of the follow-up period, 21 patients (70% of the initial sample) were no longer classified as having CKD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.